Sk Bioscience Co., Ltd.

This study tests a new chickenpox vaccine (NBP608) in 780 children aged 1 to 12 years. Researchers will compare it to existing vaccines to see if it is safe and triggers a strong immune response. Participants will receive one or two doses and be monitored for about 15 months.